{"id":420,"date":"2025-02-19T13:30:12","date_gmt":"2025-02-19T18:30:12","guid":{"rendered":"https:\/\/blog.pharmadiversityjobboard.com\/?p=420"},"modified":"2025-02-19T13:30:14","modified_gmt":"2025-02-19T18:30:14","slug":"why-pharma-collaboration-is-reshaping-disease-modeling-in-2025","status":"publish","type":"post","link":"https:\/\/blog.pharmadiversityjobboard.com\/?p=420","title":{"rendered":"Why Pharma Collaboration is Reshaping Disease Modeling in 2025"},"content":{"rendered":"\n<p>Drug development faces a significant challenge: <a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.technologynetworks.com\/drug-discovery\/online-events\/innovations-in-disease-modeling-2025-395497\">28% of medications<\/a> leave the US market because of unexpected heart-related side effects. This stark reality, combined with 400 million people worldwide affected by rare diseases, makes pharmaceutical collaboration more vital than ever.<\/p>\n\n\n\n<p>Pharmaceutical companies are reshaping their approach to disease modeling. Roche&#8217;s Institute of Human Biology, launched in 2023, shows the evolution of lab-pharma collaboration. The combination of academic research and practical applications helps biotech pharma collaboration create more reliable predictive models that represent the human body better.<\/p>\n\n\n\n<p>This piece will get into how these partnerships reshape disease modeling. We&#8217;ll explore the factors driving successful collaborations and discuss practical frameworks to build effective partnerships in 2025.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">The Evolution of Disease Modeling<\/h2>\n\n\n\n<blockquote class=\"wp-block-quote\">\n<p>&#8220;Since our last Download Day, which was approximately 18 months ago, we have seen various industries increasingly embrace AI\/ML solutions. This adoption has also played out in the drug discovery space,&#8221; \u2014 <a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/ir.recursion.com\/news-releases\/news-release-details\/recursion-gives-guidance-seven-clinical-readouts-within-18\"><strong>Chris Gibson<\/strong>, <em>Co-Founder and CEO of Recursion<\/em><\/a><\/p>\n<\/blockquote>\n\n\n\n<p>Disease progression modeling forms the foundation of pharmaceutical research. This approach combines disease history information and population characteristics to learn about disease progression <a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.strategyand.pwc.com\/de\/en\/industries\/pharma-life-sciences\/partnering-better-healthcare-system.html\"><sup>[1]<\/sup><\/a>. The original modeling approaches used pharmacokinetic and pharmacodynamic models. These models received most important recognition when the Coalition Against Major Diseases received <a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.2873\">regulatory endorsement from FDA and EMA<\/a> for its Alzheimer&#8217;s disease clinical trial simulation tool <a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.strategyand.pwc.com\/de\/en\/industries\/pharma-life-sciences\/partnering-better-healthcare-system.html\"><sup>[1]<\/sup><\/a>.<\/p>\n\n\n\n<p>The rise of collaborative platforms has revolutionized how researchers approach disease modeling. Open-source tools like the Spatiotemporal Epidemiological Modeler (STEM) help multi-disciplinary teams to add, compare, and confirm different scenarios without rewriting entire programs <a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/globalbiodefense.com\/2016\/01\/28\/open-source-disease-modeling-a-tool-to-combat-the-next-pandemic\/\"><sup>[2]<\/sup><\/a>. These platforms come loaded with vital data on:<\/p>\n\n\n\n<ul>\n<li>National borders and transportation networks<\/li>\n\n\n\n<li>Environmental conditions<\/li>\n\n\n\n<li>Air travel patterns<\/li>\n\n\n\n<li>Population demographics<\/li>\n<\/ul>\n\n\n\n<p>Digital transformation has sparked unprecedented changes in healthcare delivery systems. The integration of artificial intelligence and machine learning has boosted the assessment of longitudinal factors that include demographics, clinical data, and imaging information <a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.strategyand.pwc.com\/de\/en\/industries\/pharma-life-sciences\/partnering-better-healthcare-system.html\"><sup>[1]<\/sup><\/a>. On top of that, modern statistical inference methods now aid the incorporation of behavioral sciences data into disease models <a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/biotech-spain.com\/en\/articles\/strategic-alliances-partnering-for-success-in-the-global-pharma-market\/\"><sup>[3]<\/sup><\/a>.<\/p>\n\n\n\n<p>The move toward digital platforms has revolutionized pharma collaboration especially when you have improved data interoperability and patient-centered care approaches <a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10163407\/\"><sup>[4]<\/sup><\/a>. Modern disease modeling benefits from cloud computing, artificial intelligence, and the Internet of Things. These technologies create more sophisticated and accurate predictive models <a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9963556\/\"><sup>[5]<\/sup><\/a>. These advances have made disease modeling <a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2949866X24001084\">more precise and affordable<\/a> and enabled faster drug development processes <a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2949866X24001084\"><sup>[6]<\/sup><\/a>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Key Drivers of Pharma Collaboration<\/h2>\n\n\n\n<p>Pharmaceutical companies struggle with a harsh reality &#8211; R&amp;D costs for each new drug <a rel=\"noreferrer noopener\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S135964462400285X\" target=\"_blank\">now exceed USD 3.50 billion<\/a> <a rel=\"noreferrer noopener\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S135964462400285X\" target=\"_blank\"><sup>[7]<\/sup><\/a>. A five-decade decline in R&amp;D efficiency <a rel=\"noreferrer noopener\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S135964462400285X\" target=\"_blank\"><sup>[7]<\/sup><\/a> combined with this financial strain makes collaboration between pharma companies crucial to develop drugs sustainably.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Cost reduction benefits<\/h3>\n\n\n\n<p>Pharma collaboration offers remarkable financial advantages. Companies can make smarter R&amp;D investment decisions when they share resources across therapeutic areas <a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.bain.com\/insights\/collaborating-for-better-research-and-development-productivity\/\"><sup>[8]<\/sup><\/a>. The numbers tell a compelling story &#8211; collaborative business models have shown they can:<\/p>\n\n\n\n<ul>\n<li><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.bain.com\/insights\/collaborating-for-better-research-and-development-productivity\/\">Boost ROI from 4% to 9%<\/a> <a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.bain.com\/insights\/collaborating-for-better-research-and-development-productivity\/\"><sup>[8]<\/sup><\/a><\/li>\n\n\n\n<li>Slash clinical testing costs by 80% <a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK210038\/\"><sup>[9]<\/sup><\/a><\/li>\n\n\n\n<li>Cut down on duplicate infrastructure investments <a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK210038\/\"><sup>[9]<\/sup><\/a><\/li>\n\n\n\n<li>Save 10% on maintenance through shared preventive strategies <a rel=\"noreferrer noopener\" href=\"https:\/\/www.us.endress.com\/en\/industry-expertise\/life-sciences\/cost-reduction-pharmaceutical-industry\" target=\"_blank\"><sup>[10]<\/sup><\/a><\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Faster drug development<\/h3>\n\n\n\n<p>A new drug typically takes about 12 years to go from candidate nomination to launch <a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.mckinsey.com\/industries\/life-sciences\/our-insights\/fast-to-first-in-human-getting-new-medicines-to-patients-more-quickly\"><sup>[11]<\/sup><\/a>. Mutually beneficial alliances between companies can speed up drug development significantly. Companies now complete first-in-human studies 40% faster, taking just 12-15 months <a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.mckinsey.com\/industries\/life-sciences\/our-insights\/fast-to-first-in-human-getting-new-medicines-to-patients-more-quickly\"><sup>[11]<\/sup><\/a>.<\/p>\n\n\n\n<p>Multiple reviewers analyzing combined datasets drives this speedup, which boosts statistical power and minimizes bias <a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK210038\/\"><sup>[9]<\/sup><\/a>. Companies working on 3-5 investigational drugs yearly can generate over USD 400 million in risk-adjusted value by saving 9-12 months across their portfolio <a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.mckinsey.com\/industries\/life-sciences\/our-insights\/fast-to-first-in-human-getting-new-medicines-to-patients-more-quickly\"><sup>[11]<\/sup><\/a>.<\/p>\n\n\n\n<p>Resource sharing lets companies expand into more therapeutic areas <a rel=\"noreferrer noopener\" href=\"https:\/\/www.bain.com\/insights\/collaborating-for-better-research-and-development-productivity\/\" target=\"_blank\"><sup>[8]<\/sup><\/a>. Teams can focus their resources better by eliminating duplicate research <a rel=\"noreferrer noopener\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK210038\/\" target=\"_blank\"><sup>[9]<\/sup><\/a>. This approach helps tremendously with rare disease research, where collaborative teams work together to overcome the lack of data <a rel=\"noreferrer noopener\" href=\"https:\/\/dualitytech.com\/blog\/how-public-health-benefits-from-collaboration-on-sensitive-data\/\" target=\"_blank\"><sup>[12]<\/sup><\/a>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Building Successful Lab-Pharma Partnerships<\/h2>\n\n\n\n<blockquote class=\"wp-block-quote\">\n<p>&#8220;Those among us who are unwilling to expose their ideas to the hazard of refutation do not take part in the game of science.&#8221; \u2014 <a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/en.wikipedia.org\/wiki\/Scientific_method\"><strong>Karl Popper<\/strong>, <em>Philosopher of Science<\/em><\/a><\/p>\n<\/blockquote>\n\n\n\n<p>Lab-pharma partnerships need well-laid-out frameworks and clear guidelines to work. Studies show that <a rel=\"noreferrer noopener\" href=\"https:\/\/www.law.com\/therecorder\/2023\/11\/16\/6-ways-to-navigate-pharmaceutical-partnerships-and-disputes\/\" target=\"_blank\">over 60% of pharmaceutical collaborations end in failure<\/a> <a rel=\"noreferrer noopener\" href=\"https:\/\/www.law.com\/therecorder\/2023\/11\/16\/6-ways-to-navigate-pharmaceutical-partnerships-and-disputes\/\" target=\"_blank\"><sup>[13]<\/sup><\/a>. We failed to plan adequately and set clear expectations.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Data sharing frameworks<\/h3>\n\n\n\n<p>Note that data sharing models fall into two distinct categories <a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9118011\/\"><sup>[14]<\/sup><\/a>:<\/p>\n\n\n\n<ul>\n<li>Controlled-access sharing with milestone-based timelines<\/li>\n\n\n\n<li>Open-access sharing with direct data transfer<\/li>\n\n\n\n<li>Federated analysis where partners conduct synchronized studies<\/li>\n<\/ul>\n\n\n\n<p>These frameworks must protect participant privacy and maximize research value. Collaborative data sharing has improved transparency and created opportunities. External researchers can analyze, combine, and build upon previous evidence <a rel=\"noreferrer noopener\" href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9118011\/\" target=\"_blank\"><sup>[14]<\/sup><\/a>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Legal considerations<\/h3>\n\n\n\n<p><a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.techtarget.com\/pharmalifesciences\/feature\/8-Steps-to-Negotiating-Successful-Pharmaceutical-Partnerships\">Intellectual property rights are the life-blood<\/a> of any pharmaceutical partnership <a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.techtarget.com\/pharmalifesciences\/feature\/8-Steps-to-Negotiating-Successful-Pharmaceutical-Partnerships\"><sup>[15]<\/sup><\/a>. Determining IP ownership, licensing, and commercialization rights early in the partnership is significant. Compliance with regulatory requirements needs thorough understanding of standards and guidelines <a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.techtarget.com\/pharmalifesciences\/feature\/8-Steps-to-Negotiating-Successful-Pharmaceutical-Partnerships\"><sup>[15]<\/sup><\/a>.<\/p>\n\n\n\n<p>Trust and transparency help build fruitful partnerships <a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.techtarget.com\/pharmalifesciences\/feature\/8-Steps-to-Negotiating-Successful-Pharmaceutical-Partnerships\"><sup>[15]<\/sup><\/a>. Clear protocols should be established for:<\/p>\n\n\n\n<ul>\n<li>Data protection and confidentiality<\/li>\n\n\n\n<li>Informed consent management<\/li>\n\n\n\n<li>Risk and reward sharing<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Resource allocation<\/h3>\n\n\n\n<p>Resource management works best when companies evaluate contract structure early in the partnership <a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.statnews.com\/2019\/03\/05\/global-partnerships-pharma-success\/\"><sup>[16]<\/sup><\/a>. Partnership formation timing affects both risk and potential rewards by a lot. Small biotech companies face a vital decision: partner early to reduce risk or wait until reaching specific milestones to maximize potential gains <a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.universitylabpartners.org\/blog\/tips-for-partnering-with-big-pharma\"><sup>[17]<\/sup><\/a>.<\/p>\n\n\n\n<p>Pharmaceutical companies should assign dedicated alliance managers to handle daily administrative tasks and information flow for optimal resource allocation <a rel=\"noreferrer noopener\" href=\"https:\/\/www.statnews.com\/2019\/03\/05\/global-partnerships-pharma-success\/\" target=\"_blank\"><sup>[16]<\/sup><\/a>. This approach smooths the onboarding process and maintains consistent communication between partners effectively.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Measuring Collaboration Success<\/h2>\n\n\n\n<p>Pharma collaborations need clear metrics and verified assessment tools to measure success. Research reveals that <a rel=\"noreferrer noopener\" href=\"https:\/\/www.strategyand.pwc.com\/de\/en\/industries\/pharma-life-sciences\/partnering-better-healthcare-system.html\" target=\"_blank\">85% of pharma executives<\/a> see partnerships as vital, but half of them report failure rates that substantially exceed 60% <a rel=\"noreferrer noopener\" href=\"https:\/\/www.strategyand.pwc.com\/de\/en\/industries\/pharma-life-sciences\/partnering-better-healthcare-system.html\" target=\"_blank\"><sup>[1]<\/sup><\/a>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Key performance metrics<\/h3>\n\n\n\n<p>Specific performance indicators are the foundations of successful collaborations. The main goal is to evaluate partnership effectiveness through:<\/p>\n\n\n\n<ul>\n<li>Revenue generation and profitability tracking<\/li>\n\n\n\n<li>State-of-the-art and new product development progress<\/li>\n\n\n\n<li>Market share expansion measurements<\/li>\n\n\n\n<li>Patient outcomes and satisfaction rates <a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/biotech-spain.com\/en\/articles\/strategic-alliances-partnering-for-success-in-the-global-pharma-market\/\"><sup>[3]<\/sup><\/a><\/li>\n<\/ul>\n\n\n\n<p>These metrics need consistent monitoring through verified measurement instruments. Studies show 44 measures of research collaboration quality exist, and all but one of these measures show statistical validity <a rel=\"noreferrer noopener\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31660251\/\" target=\"_blank\"><sup>[18]<\/sup><\/a>. All the same, most current partnership measures lack proper verification and we mainly focus on new partnerships instead of long-standing ones <a rel=\"noreferrer noopener\" href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7439287\/\" target=\"_blank\"><sup>[19]<\/sup><\/a>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Return on investment analysis<\/h3>\n\n\n\n<p>ROI analysis is a vital tool to evaluate pharma collaborations. ROI calculations differ between studies that focus only on fiscal savings and those that include broader benefits <a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/gh.bmj.com\/content\/8\/8\/e012798\"><sup>[20]<\/sup><\/a>. Disease management programs that work well show an <a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC4194913\/\">average ROI of USD 2.78 per dollar invested<\/a> <a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC4194913\/\"><sup>[21]<\/sup><\/a>.<\/p>\n\n\n\n<p>Organizations should look at both process-based and outcome-based metrics to get a full picture of ROI <a rel=\"noreferrer noopener\" href=\"https:\/\/www.appliedclinicaltrialsonline.com\/view\/performance-metrics-optimizing-outcomes\" target=\"_blank\"><sup>[22]<\/sup><\/a>. Financial outcomes show how teams use project budgets, while study team satisfaction ratings give an explanation of customer-sponsor relationships <a rel=\"noreferrer noopener\" href=\"https:\/\/www.appliedclinicaltrialsonline.com\/view\/performance-metrics-optimizing-outcomes\" target=\"_blank\"><sup>[22]<\/sup><\/a>. This complete approach helps partnerships spot areas for improvement and make smart decisions about resources.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Conclusion<\/h2>\n\n\n\n<p>Pharmaceutical collaborations drive disease modeling and drug development forward in 2025. Research partnerships yield impressive results, <a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.technologynetworks.com\/drug-discovery\/online-events\/innovations-in-disease-modeling-2025-395497\">cutting development costs by up to 80%<\/a> and reducing time-to-market by 40%. These wins come from shared resources, combined datasets and coordinated research efforts.<\/p>\n\n\n\n<p>The numbers paint a clear picture. Past pharma partnerships failed 60% of the time, but modern collaborative frameworks show better results. Strong foundations for lasting partnerships now exist through strategic data sharing, clear legal guidelines and dedicated alliance management.<\/p>\n\n\n\n<p>Measurement tools and ROI analysis help evaluate partnerships effectively. Companies that use confirmed assessment methods and detailed performance metrics set themselves up for long-term growth. Organizations that focus on process-based and outcome-based metrics show better resource allocation and higher study team satisfaction.<\/p>\n\n\n\n<p>Disease modeling advances through technology and cross-industry teamwork. The pharmaceutical research landscape changes rapidly, and successful collaborations remain vital to developing better treatments and improving patient outcomes worldwide.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">References<\/h2>\n\n\n\n<p>[1] &#8211; <a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.strategyand.pwc.com\/de\/en\/industries\/pharma-life-sciences\/partnering-better-healthcare-system.html\">https:\/\/www.strategyand.pwc.com\/de\/en\/industries\/pharma-life-sciences\/partnering-better-healthcare-system.html<\/a><br>[2] &#8211; <a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/globalbiodefense.com\/2016\/01\/28\/open-source-disease-modeling-a-tool-to-combat-the-next-pandemic\/\">https:\/\/globalbiodefense.com\/2016\/01\/28\/open-source-disease-modeling-a-tool-to-combat-the-next-pandemic\/<\/a><br>[3] &#8211; <a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/biotech-spain.com\/en\/articles\/strategic-alliances-partnering-for-success-in-the-global-pharma-market\/\">https:\/\/biotech-spain.com\/en\/articles\/strategic-alliances-partnering-for-success-in-the-global-pharma-market\/<\/a><br>[4] &#8211; <a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10163407\/\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10163407\/<\/a><br>[5] &#8211; <a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9963556\/\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9963556\/<\/a><br>[6] &#8211; <a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2949866X24001084\">https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2949866X24001084<\/a><br>[7] &#8211; <a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S135964462400285X\">https:\/\/www.sciencedirect.com\/science\/article\/pii\/S135964462400285X<\/a><br>[8] &#8211; <a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.bain.com\/insights\/collaborating-for-better-research-and-development-productivity\/\">https:\/\/www.bain.com\/insights\/collaborating-for-better-research-and-development-productivity\/<\/a><br>[9] &#8211; <a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK210038\/\">https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK210038\/<\/a><br>[10] &#8211; <a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.us.endress.com\/en\/industry-expertise\/life-sciences\/cost-reduction-pharmaceutical-industry\">https:\/\/www.us.endress.com\/en\/industry-expertise\/life-sciences\/cost-reduction-pharmaceutical-industry<\/a><br>[11] &#8211; <a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.mckinsey.com\/industries\/life-sciences\/our-insights\/fast-to-first-in-human-getting-new-medicines-to-patients-more-quickly\">https:\/\/www.mckinsey.com\/industries\/life-sciences\/our-insights\/fast-to-first-in-human-getting-new-medicines-to-patients-more-quickly<\/a><br>[12] &#8211; <a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/dualitytech.com\/blog\/how-public-health-benefits-from-collaboration-on-sensitive-data\/\">https:\/\/dualitytech.com\/blog\/how-public-health-benefits-from-collaboration-on-sensitive-data\/<\/a><br>[13] &#8211; <a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.law.com\/therecorder\/2023\/11\/16\/6-ways-to-navigate-pharmaceutical-partnerships-and-disputes\/\">https:\/\/www.law.com\/therecorder\/2023\/11\/16\/6-ways-to-navigate-pharmaceutical-partnerships-and-disputes\/<\/a><br>[14] &#8211; <a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9118011\/\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9118011\/<\/a><br>[15] &#8211; <a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.techtarget.com\/pharmalifesciences\/feature\/8-Steps-to-Negotiating-Successful-Pharmaceutical-Partnerships\">https:\/\/www.techtarget.com\/pharmalifesciences\/feature\/8-Steps-to-Negotiating-Successful-Pharmaceutical-Partnerships<\/a><br>[16] &#8211; <a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.statnews.com\/2019\/03\/05\/global-partnerships-pharma-success\/\">https:\/\/www.statnews.com\/2019\/03\/05\/global-partnerships-pharma-success\/<\/a><br>[17] &#8211; <a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.universitylabpartners.org\/blog\/tips-for-partnering-with-big-pharma\">https:\/\/www.universitylabpartners.org\/blog\/tips-for-partnering-with-big-pharma<\/a><br>[18] &#8211; <a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31660251\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/31660251\/<\/a><br>[19] &#8211; <a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7439287\/\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7439287\/<\/a><br>[20] &#8211; <a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/gh.bmj.com\/content\/8\/8\/e012798\">https:\/\/gh.bmj.com\/content\/8\/8\/e012798<\/a><br>[21] &#8211; <a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC4194913\/\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC4194913\/<\/a><br>[22] &#8211; <a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.appliedclinicaltrialsonline.com\/view\/performance-metrics-optimizing-outcomes\">https:\/\/www.appliedclinicaltrialsonline.com\/view\/performance-metrics-optimizing-outcomes<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Drug development faces a significant challenge: 28% of medications leave the US market because of unexpected heart-related side effects. This stark reality, combined with 400 million people worldwide affected by rare diseases, makes pharmaceutical collaboration more vital than ever. Pharmaceutical companies are reshaping their approach&#46;&#46;&#46;<\/p>\n","protected":false},"author":1,"featured_media":422,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"spay_email":""},"categories":[12,4,35,64],"tags":[103,100,117,69,113,104,105,114,108,110,102,106,112,101,116,67,109,107,111,115],"jetpack_featured_media_url":"https:\/\/blog.pharmadiversityjobboard.com\/wp-content\/uploads\/2025\/02\/55edf7a8-fa2d-4fb2-9eeb-0cc60d224d01.png","_links":{"self":[{"href":"https:\/\/blog.pharmadiversityjobboard.com\/index.php?rest_route=\/wp\/v2\/posts\/420"}],"collection":[{"href":"https:\/\/blog.pharmadiversityjobboard.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blog.pharmadiversityjobboard.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blog.pharmadiversityjobboard.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/blog.pharmadiversityjobboard.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=420"}],"version-history":[{"count":1,"href":"https:\/\/blog.pharmadiversityjobboard.com\/index.php?rest_route=\/wp\/v2\/posts\/420\/revisions"}],"predecessor-version":[{"id":421,"href":"https:\/\/blog.pharmadiversityjobboard.com\/index.php?rest_route=\/wp\/v2\/posts\/420\/revisions\/421"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/blog.pharmadiversityjobboard.com\/index.php?rest_route=\/wp\/v2\/media\/422"}],"wp:attachment":[{"href":"https:\/\/blog.pharmadiversityjobboard.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=420"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blog.pharmadiversityjobboard.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=420"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blog.pharmadiversityjobboard.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=420"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}